A sol-gel vault which comprises a complex between a vault particle and a sol-gel. The vault particle comprises one or more one or more passenger molecules. At least one of the one or more passenger molecules is an mINT passenger molecule. At least one of the one or more passenger molecules is a protein. At least one of the one or more passenger molecules is an enzyme. The sol-gel is a silica-based sol-gel.

Provided herein are methods of treatment, compositions, systems and kits using polymer particles as restraints of neutrophil function. Such methods include, but are not limited to, methods of preventing, treating, and/or ameliorating inflammatory diseases, infections, autoimmune diseases, malignant diseases, and other diseases or conditions in which neutrophils may be implicated. In some embodiments, polymer particles are useful for diagnosing neutrophil related diseases or conditions.

A method of coating a peptide or protein useful for improving the cellular activity related to bone growth on an inorganic particle comprises the steps of freezing the residual liquid present on uncoated and or coated inorganic particles, and drying the uncoated or coated inorganic particles after freezing the residual liquid, the drying comprising causing the frozen residual liquid to sublime under vacuum. Further disclosed embodiments of the invention include further processes for forming inorganic particles coated with a peptide or protein useful for improving cellular activity related to bone growth and medical devices comprising the coated particles.

Phenylephrine particles suitable for solid, semi solid or liquid dosage forms are disclosed.

Bacteriophage covalently attached to a carrier particle with an average diameter of from 0.1 microns to 15 microns, are used in topical treatment of bacterial infection. Bacteriophage covalently attached to a carrier particle of average diameter 7 microns or less are used in systemic treatment of bacterial infection. A plurality of bacteriophages lytic against different bacterial strains gives wide antibacterial activity. A combination therapy comprises administration of antibiotic and bacteriophage covalently attached to a carrier particle.

Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents.

The invention features methods and compositions for (i) controlling the amount of peptide bound to calcium phosphate particles; and (ii) for tightly binding peptide to the surface of calcium phosphate particles. The methods and compositions can be useful for preparing implants useful for promoting bone deposition at the site of implantation, and for repairing a variety of orthopedic conditions.

Described herein are suspensions of helical polycarbodiimide polymers that ‘cloak’ nanotubes, thereby effecting control over nanotube emission, providing a new mechanism of environmental responsivity, and enabling precise control over sub-cellular localization. The helical polycarbodiimide polymers described herein are water soluble, easily modifiable, and have unique architectures that facilitate their application in radiopharmaceutical delivery and imaging methods, in therapeutics and therapeutic delivery methods, and their use as sensors—both in conjunction with carbon nanotubes, and without nanotubes.

Non-linear multiblock copolymer-drug conjugates for the treatment and prevention of diseases and disorders of the eye are provided. The polymer-drug conjugates can form nanoparticles, microparticles, and implants that are capable of effectively delivering therapeutic levels of one or more active agents for an extended period of time. Administration to the eye of an active agent in the form of a non-linear multiblock copolymer-drug conjugate produces decreased side effects when compared to administration of the active agent alone. Also provided are methods of treating intraocular neovascular diseases, such as wet age-related macular degeneration as well as diseases and disorders of the eye associated with inflammation, such as uveitis.

The present invention relates to a drug-coated microneedle and a method of manufacturing the same, and more particularly to a drug-coated microneedle that delivers a drug by physically piercing the stratum corneum of the skin and a method of manufacturing the same. The drug-coated microneedle is represented by Chemical Formula 1 below, and is capable of releasing a drug through a redox reaction after penetration into the skin. The drug-coated microneedle according to the present invention is capable of effectively delivering a drug having excellent functionality but low skin permeability, and is thus useful as a material for functional cosmetics for whitening, wrinkle reduction, inflammation reduction and the like. [Chemical Formula 1] MN-S—S-D. In Chemical Formula 1, MN is a silica-(SiO.sub.2)-containing microneedle, S—S is a disulfide bond, and D is a drug.